Company Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada.
The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.
ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Neil K. Warma M.B.A. |
Contact Details
Address: Suite 200, 1920 Yonge Street Toronto, A6 M4S 3E2 Ontario, Canada | |
| Phone | 416-847-6898 |
| Website | promisneurosciences.com |
Stock Details
| Ticker Symbol | PMN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374339 |
| CUSIP Number | 74346M406 |
| ISIN Number | CA74346M4065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neil K. Warma M.B.A. | President, Interim Chief Executive Officer, Principal Executive Officer and Director |
| Eugene Williams | Co-Founder and Chairman |
| Dr. Neil R. Cashman M.D. | Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer and Director |
| Gavin T. Malenfant | Chief Operating Officer |
| Daniel E. Geffken M.B.A. | Chief Financial Officer |
| Dr. Johanne Kaplan Ph.D. | Chief Development Officer |
| Dr. Ernest D. Bush Ph.D. | Head of Pharmacology/Toxicology and Senior Consultant |
| Dr. David Wishart Ph.D. | Chief Physics Officer |
| Dennis Chen Ph.D. | Head of Manufacturing and Senior Consultant |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 5, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 30, 2024 | 8-K | Current Report |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 424B5 | Filing |
| Apr 1, 2024 | 10-K | Annual Report |